Achilles Therapeutics plc (ACHL) Reports In-Line Q2 EPS

Achilles Therapeutics plc (NASDAQ: ACHL) reported Q2 EPS of ($0.41), in-line with the analyst estimate of ($0.41).

For earnings history and earnings-related data on Achilles Therapeutics plc (ACHL) click here.

You May Also Be Interested In

• NVIDIA, Mitsubishi Heavy Industries eye cooperation on AI data center cooling and power - Nikkei
• PACCAR (PCAR) Declares $0.35 Quarterly Dividend; 1.1% Yield
• UBS Reiterates Buy Rating on Boot Barn (BOOT), Expects Q1 Earnings Beat